Acute myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Switzerland· EU contribution €1,499,511· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,499,423· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Germany· EU contribution €1,491,735· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 26 running projects, newest first. Listed amounts together: €53.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Computational deconvolution of drug sensitivity via single-cell-to-bulk transcriptome mapping.

  PLoS Comput Biol, Oct 2026

• Characterization of chemoresistant cell populations improves risk stratification and therapy prediction in pediatric acute myeloid leukemia.

  Nat Commun, Oct 2026

• Unifying multimodal single-cell data with a mixture-of-experts β-variational autoencoder framework.

  Genome Res, Oct 2026

• Integrative single-cell and bulk transcriptomics define polyamine-associated cell states in acute myeloid leukemia and implicate CCT6A in polyamine homeostasis.

  Front Immunol, Sept 2026

• Single-cell chromatin profiling reveals relapse-related priming in pediatric acute myeloid leukemia.

  Life Sci Alliance, Aug 2026

• Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

  Blood, Jul 2026

• Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

  Blood Adv, Jul 2026

• Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia.

  Nature, Jul 2026

• Quantitative single-cell analysis of PML-RARα oncogene-induced DNA damage along cell cycle progression.

  Methods, Jul 2026

• Single-cell RNA sequencing reveals immunological heterogeneity of the tumor microenvironment in acute myeloid leukemia.

  Adv Clin Exp Med, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.